Iovance Biotherapeutics, Inc. (IOVA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$7.74-11.03%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · IOVA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -36.0% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 48.0% |
Growth built into the price is above our model estimate.
The price assumes 84.0 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 117 industry peers
IOVA — earnings miss
Dated 2026-05-07
Results of Operations and Financial Condition. On May 7, 2026, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026, and an update on recent developments. A copy of that press release is furnished as Exhibit 99.1. The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 193…
Why it matters: The final data will test whether the response signal holds in the broader group, not just the selected subgroup.
Supportive ifThe final dataset includes about 80 patients and confirms responses on review. It supports an sBLA filing in 2027.
Worry ifThe final response rate falls well below the reported 24.6%, or the filing is delayed or dropped.
Why it matters: Sales are growing, but Iovance still reports losses. Better margins would show progress toward covering costs.
Supportive ifQuarterly operating losses fall from Q2's $51.9M. Gross margin stays near or above Q2's reported 56%.
Worry ifOperating losses widen from $51.9M or gross margin falls well below the reported Q2 level.
Why it matters: FDA feedback can show whether this small, selected study can support a path to approval.
Watch forIovance reports FDA support for a path to registration using the planned study. The study selects patients by biomarkers.
Also watch forFDA asks for a larger or different study, or does not support the proposed path.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$307 on $10,000 · ±3.1% | How much price usually moves either way. |
| Bad day | $787 loss on $10,000 · 7.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,791 loss on $10,000 · 47.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.